SAT0647 MRI DATA FROM THE SPRIFERMIN PHASE II FORWARD STUDY: CONFIRMATION OF MANUAL CARTILAGE SEGMENTATION FINDINGS BY AUTOMATED SEGMENTATION
Authors: Alan Brett, Michael A. Bowes, Philip G. Conaghan, Christoph Ladel, Jeffrey Kraines, Hans Gühring, Flavie Moreau, Felix Eckstein
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> Sprifermin is under investigation as a potential disease-modifying osteoarthritis drug (DMOAD). 2-yr results from the FORWARD study showed significant dose-dependent modification of cartilage thickness in the total femorotibial joint (TFTJ), medial and lateral femorotibial joints (MFTC, LFTC), and central medial and lateral TFTJ subregions, by quantitative (q)MRI.<sup>1</sup> <h3>Objectives</h3> To determine whether qMRI findings from FORWARD (manual segmentation) could be reproduced in the same cartilage regions using an independent method (automated segmentation), on the same dataset/time period. <h3>Methods</h3> Pts were randomized 1:1:1:1:1 to: sprifermin 100 μg q6mo; 100 μg q12mo; 30 μg q6mo; 30 μg q12mo; and placebo (n=110/110/111/110/108).<sup>1</sup> Cartilage thickness was assessed at baseline and 6, 12, 18, and 24 months using 1.5- or 3-Tesla MRI images, analyzed manually.<sup>1</sup> The same images were analyzed by automated cartilage segmentation using active appearance models, a supervised machine learning method, to produce maps of cartilage thickness for weight-bearing femoral and tibial cartilage surfaces, subdivided into anatomical masks. Results were blinded for treatment and timepoint for both methods. No statistical comparisons between methods were conducted. Endpoints were change from baseline in: 1) cartilage thickness in the TFTJ, MFTC and LFTC, using regions duplicated based on published data;<sup>1</sup> 2) cartilage thickness in the central subregion of the medial and lateral tibia and femur (cMT, cMF, cLT, cLF [conventions used by the automated analysis investigators]). As in previous analyses, treatment effect was assessed by observed changes and adjusted using repeated ANCOVA on change from baseline, including treatment group, timepoint, and country as fixed factors, baseline value as covariate and treatment by timepoint as interaction. <h3>Results</h3> Based on automated segmentation, statistically significant, dose-dependent structural modification of cartilage thickness was observed over 2 yrs with sprifermin vs placebo for the TFTJ (overall treatment effect and dose response across all doses, both P&lt;0.001), MFTC (P=0.004 and P=0.044), and LFTC (both P&lt;0.001). <b>Table 1</b> shows changes from baseline for sprifermin 100 μg q6mo and placebo. Statistically significant dose-dependent structural modification of cartilage over 2 yrs was observed for sprifermin vs placebo in the cMT (100 μg q6mo), cLT (100 μg q6mo, q12mo) and cLF (100 μg q6mo, q12mo). In the cMF, there was no treatment effect, but there was a linear trend for dose responsiveness. The results showed a consistent pattern to those obtained using manual segmentation. <h3>Conclusion</h3> Cartilage thickness assessed by automated segmentation provided a consistent pattern of structural modification in FORWARD compared with manual segmentation. This is the first time that two independent methods of image analysis have reached the same conclusions in an interventional DMOAD trial. The findings strengthen the conclusions that sprifermin modifies cartilage loss/structural progression in knee OA. <h3>References</h3> [1] Hochberg, et al. ACR 2017 <h3>Disclosure of Interests</h3> Alan Brett Employee of: Employee of Imorphics, Manchester, UK, Michael A Bowes Employee of: Employee of Imorphics, Manchester, UK, Philip G Conaghan Consultant for: Flexion Therapeutics, AbbVie, Medivir, Merck Serono, Novartis, GlaxoSmithKline, Christoph Ladel Employee of: Employee of Merck KGaA, Darmstadt, Germany, Jeffrey Kraines Employee of: Employee of EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Hans Gühring Employee of: Employee of Merck KGaA, Darmstadt, Germany, Flavie Moreau Employee of: Employee of EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Felix Eckstein Shareholder of: Shareholder of Chondrometrics GmbH, Consultant for: Consulting fees from Merck KGaA, Samumed LLC, Abbvie, Bioclinica, TissueGene, Servier, and Roche, Employee of: Employee of Chondrometrics GmbH